Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan.
1. The present study investigates the effects of selective and a non-selective monoamine oxidase (MAO) inhibitors combined with L-tryptophan on MAO-A and -B activity, hypothalamic extracellular 5-hydroxytryptamine (5-HT) in vivo and the occurrence of the 5-HT behavioural syndrome. 2. Selective inhibition of intraneuronal MAO-A with MDL 72394 (0.5 mg kg-1, i.p.) had no effect on extracellular 5-HT and following administration of L-tryptophan (50 mg kg-1, i.p.) the 5-HT behavioural syndrome was not induced. 3. Selective inhibition of MAO-A at all sites with clorgyline (5 mg kg-1, i.p.) increased extracellular 5-HT but did not induce the 5-HT behavioural syndrome when combined with L-tryptophan administration. 4. Selective inhibition of MAO-B with selegiline (10 mg kg-1, i.p.) had no effect on extracellular 5-HT and the 5-HT behavioural syndrome was not observed after L-tryptophan administration. 5. Inhibition of MAO-A and -B with a higher and therefore non-selective, dose of MDL 72394 (2 mg kg-1) markedly increased extracellular 5-HT but failed to induce the 5-HT behavioural syndrome after L-tryptophan administration. 6. Inhibition of MAO-A and -B at all sites in the brain (tranylcypromine 20 mg kg-1, i.p. or clorgyline 5 mg kg-1 plus selegiline 10 mg kg-1) increased extracellular 5-HT and induced the behavioural syndrome on administration of L-tryptophan. 7. The results demonstrate that inhibition of MAO-A and -B both within amine neurones and elsewhere in the brain is essential for the development of the 5-HT behavioural syndrome. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'. Whilst the syndrome is associated with increased extracellular 5-HT this does not appear necessarily to result in the syndrome and may indicate that increased extracellular 5-HT is not solely involved in the induction of the '5-HT behavioural syndrome'.
D006916:5-Hydroxytryptophan / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D003010:Clorgyline / Q000494:pharmacology; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007211:Indoles / Q000378:metabolism; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012642:Selegiline / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D013997:Time Factors; D014191:Tranylcypromine / Q000494:pharmacology; D014364:Tryptophan / Q000494:pharmacology*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000494:pharmacology
D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D012701:Serotonin; D014191:Tranylcypromine; D014443:Tyrosine; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; C046880:beta-fluoromethylene-3-tyrosine; D006916:5-Hydroxytryptophan; D003010:Clorgyline